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Wheezing during infancy has been linked to early loss of pulmonary function. We prospectively investigated the relation
between bronchial hyperresponsiveness (BHR) and progressive impairment of pulmonary function in a cohort of asthmatic
infants followed until age 9 years. We studied 129 infants who had had at least three episodes of wheezing. Physical
examinations, baseline lung function tests and methacholine challenge tests were scheduled at ages 16 months and 5, 7
and 9 years. Eighty-three children completed follow-up. Twenty-four (29%) infants had wheezing that persisted at 9 years of
age. Clinical outcome at age 9 years was significantly predicted by symptoms at 5 years of age and by parental atopy.
Specific airway resistance (sRaw) was altered in persistent wheezers as early as 5 years of age, and did not change
thereafter. Ninety-five per cent of the children still responded to methacholine at the end of follow-up. The degree of BHR
at 9 years was significantly related to current clinical status, baseline lung function, and parental atopy. BHR at 16 months
and 5 years of age did not predict persistent wheezing between 5 and 9 years of age, or the final degree of BHR, but it did
predict altered lung function. Wheezing that persists from infancy to 9 years of age is associated with BHR and to impaired
lung function. BHR itself is predictive of impaired lung function in children, strongly pointing to early airway remodeling in
infantile asthma.
Citation: Delacourt C, Benoist M-R, Le Bourgeois M, Waernessyckle S, Rufin P, et al (2007) Relationship between Bronchial Hyperresponsiveness and
Impaired Lung Function after Infantile Asthma. PLoS ONE 2(11): e1180. doi:10.1371/journal.pone.0001180
INTRODUCTION
Many infants wheeze during acute lower respiratory tract illness,
but the wheezing usually ceases after 3 years of age [1].
Respiratory events occurring during the first years of life, even
when transient, may influence the expression of asthma and lung
function during childhood and early adulthood [2]. Children
who wheeze from infancy to 6 years of age are at a high risk of
long-term persistent wheezing [2]. Infantile wheeze was also
recently linked to early signs of airway obstruction [2,3].
Identification of factors predictive of clinical or functional
deterioration in infants who wheeze would allow appropriate
treatment to be started early. The role of bronchial hyperrespon-
siveness in these early alterations of lung function has rarely been
investigated. It has been postulated that nonspecific bronchial
hyperresponsiveness is a risk factor for accelerated pulmonary
function decline during aging and for the onset of chronic airway
obstruction [4–6]. More recently, Palmer and coworkers showed
that early airway hyperresponsiveness was associated with
a decreased baseline FEV1 by school age [7]. We have
previously found that bronchial hyperresponsiveness persisted at
5 years of age in all children with infantile asthma, defined by
three or more wheezing episodes before 2 years of age [8].
However, asthmatic infants who persisted to wheeze at 5 years of
age had significantly stronger bronchial hyperresponsiveness to
methacholine than children who became asymptomatic [9].
Persistent airway hyperresponsiveness may be therefore a signif-
icant contributor both to persistent symptoms and to airway
obstruction. The children who participated in our first study
were evaluated here for lung function and bronchial hyperreac-
tivity at seven and nine years of age. We found that persistent
infantile asthma was associated with an early increase in airway
responsiveness, which likely contributed to impaired pulmonary
function.
METHODS
Subjects and Study Design
The study was approved by the ethics committee of Necker-
Enfants Malades Hospital, and informed consent was obtained
from the parents of all the children.
The cohort on which this study was based has been described in
detail elsewhere [9]. Briefly, 129 infants who had had at least three
episodes of wheezing were recruited at the Paediatric Chest Unit of
Necker-Enfants Malades Hospital in Paris. Their mean age
(6standard deviation) at enrolment was 1667m o n t h s( r a n g e1 1t o
24 mo). One hundred and twelve of these children were evaluated
4 years later, and results were previously published [9]. After this
evaluation at 5 years of age, the children had a physical examination,
lung function tests and a methacholine challenge test every 2 years
until the age of 9 years. Eighty-three children (57 boys, 26 girls) had
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PLoS ONE | www.plosone.org 1 November 2007 | Issue 11 | e1180all the evaluations and formed the basis for the present study. At each
evaluation, children with wheezing during the past year were
classified as symptomatic, whereas those with no respiratory
symptoms during the past year were stated as asymptomatic.
Children were skin prick tested at 9 years of age, for at least 6 local
aeroallergens, including Dermatophagoides pteronyssinus and farinae, cat,
dog, birch and grass pollen (Stallergene SA, Antony, France).
Personal atopy was defined as one or more tests producing a wheal of
3 mm or more [10]. The child’s mother and/or father was atopic
(asthma, allergic rhinitis or atopic eczema) in 44% of cases.
Lung Function Tests
All the children had to be asymptomatic for at least 1 week before
the day of the test, which was otherwise rescheduled.
Forced vital capacity (FVC, liters) and forced expiratory volume
in one second (FEV1, liters) were measured at age 9 years by using
a Sensormedics 2400 spirometer (SEBAC-MSR, Pantin, France).
Specific airway resistance (sRaw) was measured at ages 5, 7 and
9 years by using a whole-body plethysmograph (M. Autobox,
SEBAC-MSR, Pantin, France). SRaw was calculated by simple
algebraic manipulation of the known formulas for airway resistance
and total gas volume [11]. This precludes the need for shutter
occlusion, because sRaw is derived directly from the relationship
between plethysmographic volume and respiratory flow. Measure-
ments were made with a mouthpiece and nose clip. Three
measurements of sRaw were made, and each was calculated from
the medians of five consecutively measured technically acceptable
loops [12].The meanofthesethree sRawmeasurementswasused in
theanalysis.Becauseofmethacholinechallenge,post-bronchodilator
values were not obtained.
Methacholine Challenge
The methacholine aerosol was administered with a dosimeter
(MFDC 88, Mediprom, Paris, France) attached to a nebulizer (De
Vilbis 5610 D; particle size 1.9 mm MMAD). The apparatus was
programmed to deliver a dose of 50 mg of methacholine in 40 ml of
air in 0.5 s. In these conditions the duration and volume of each
aerosol dose did not exceed the inspiratory time or volume, so each
delivered dose was completely inhaled. The dosimeter was triggered
by the inspiratory negative buccal pressure. The children initially
inhaled normal saline. SRaw was measured two minutes later. This
sequencewasrepeatedafterdatacollection.Theinitialmethacholine
dose was 50 mg and the dose was doubled for each sequence until
sRaw increased by at least 100% from baseline or until a maximal
methacholine dose of 1600 mg was inhaled. The dose provoking
a doubling of sRaw was derived from the plot of the log
methacholine dose against sRaw, by linear interpolation between
the last two points on the semilogarithmic dose–response graph.
Children who did not respond to the maximal dose of methacholine
wereassigned the value PD100=2400 mg (i.e., one half the maximal
dose). At 16 months of age, the response to methacholine was
evaluated by the fall in transcutaneous oxygen tension, and a 15%
fall was considered as a positive response (PD15Ptc02) [9].
Data Analysis
At each evaluation, children with wheezing during the past year
were classified as symptomatic, whereas those with no respiratory
symptoms during the past year were stated as asymptomatic. At
the end of the 9-year follow-up period the children were classified
into three groups:
- persistent wheezers: children classified as symptomatic
at all three evaluations
- intermittent wheezers: children intermittently classified
as symptomatic
- asymptomatic children: children classified as asymp-
tomatic at all three evaluations.
All data are expressed as the mean6standard deviation (SD). The
Kolmogorov-Smirnov test was applied to test for a normal
distribution in all parameters. At each evaluation, sRaw values were
independent of weight and height and were expressed as cmH2O.s.
FEV1 was expressed as a percentage of FVC (FEV1/FVC). Height
adjusted-V’max FRC values at age 16 months were converted to z
scores. PD15PtcO2 and PD100sRaw values were log-transformed
before analysis. For comparisons between time points, log values
were converted to z scores to make them comparable. Linear
regression and the chi2 test were used for comparisons between
continuous and qualitative variables, respectively. Analysis of
variance (ANOVA) followed by Fisher’s PLSD test was used to test
for intergroup differences. ANOVA with repeated measures was
used for between-group comparisons over time. Odds ratios were
obtained by logistic regression analysis. P values,0.05 were
considered to denote significant differences.
RESULTS
Onehundredandtwenty-nineinfantsaged16 monthswereenrolled
in this prospective study. One hundred and twelve of these children
were evaluated 4 years later and 83 attended the final visit at age
9 years. Their mean age6SD was 9.360.7 years (range 8.1–10.9).
Mean anthropometric data at each visit are summarized in Table 1.
Children losttofollow-up between 5 and 9 years ofagedid notdiffer
from children who completed the study (Table 1).
Clinical Progression
Althoughthemajorityofincludedinfantswereinapparentremission
at 5 years of age, the rate of children with wheezing increased with
age (Figure1).Symptomaticchildrenwere37%,54%,and64%at 5,
7, and 9 years of age, respectively. Twenty-four (29%) of the 83
children examined were categorized aspersistent wheezers,38 (46%)
as intermittent wheezers, and 21 (25%) as asymptomatic. Thirteen
children (16%) were taking inhaled corticosteroids (IC) at 9 years.
The majority (69%) of children with IC had persistent symptoms.
The remaining 31% had intermittent symptoms. Among the 62
children who wheezed between 5 and 9 years of age, 42 children
experienced at least one episode of breathlessness requiring oral
steroids or an emergency visit, while 20 children had two or more
such episodes. Being symptomatic at 9 years of age was significantly
Table 1. Characteristics of children who completed the study
and those who were lost to follow-up between 5 and 9 years
of age.
......................................................................
Children who
completed the
study (n=83)
Children lost to
follow-up between
5 and 9 years (n=29)
Age at final visit 9.360.7 -
Sex (% male) 68 67
% with parental atopy 44 45
% asymptomatic at 5 years 63 57
sRaw at 5 years (kPa/s) 7.962.2 7.562.9
PD100 sRaw at 5 years (log) 2.41360.374 2.24960.563
No significant difference was observed between the groups.
doi:10.1371/journal.pone.0001180.t001
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PLoS ONE | www.plosone.org 2 November 2007 | Issue 11 | e1180predicted by being symptomatic at 5 years of age (OR=4.8 (95%
CI: 1.6–14.5); p,0.006) and by parental atopy (OR=3.1 (95% CI:
1.1–8.2); p,0.03).
Skin prick tests were performed in 74 children, of whom 24
(32%) reacted to at least one allergen. No significant association
was found with clinical findings at 9 years.
Baseline lung function
Baseline sRaw was evaluated at ages 5, 7, and 9, whereas spirometry
was performed only at age 9 years. At age 9 years, mean sRaw,
FEV1, and FEV1/FVC values were 7.362.3 cmH20.s, 95.86
13.8% of predicted, and 84.767.7%, respectively. The results of
univariate analysis of factors potentially associated with baseline lung
function at 9 years of age are shown in Table 2. Previous lung
function results and the clinical history, but not current clinical
status, were significantly related to lung function results at age
9 years. In particular, symptomatic children at 5 years of age had
significantly higher sRaw levels and lower FEV1/FVC values at age
9 years. SRaw levels were already elevated at age 5 years in these
children, and did not change thereafter (Figure 2A). Children who
were asymptomatic at age 5 years continued to have low sRaw
values, independently of their clinical outcome at 9 years of age
(Figure 2B).
Airway reactivity to methacholine
Only 5% of the 9-year-old children tested did not respond to
methacholine, up to a dose of 1600 mg. We first analyzed factors
associated with PD100 sRaw values at 9 years of age (Table 3).
Lower PD100 sRaw values at 9 years were significantly related to
persistent symptoms from age 5 years to 9 years, and also with
a larger number of severe exacerbations between 5 and 9 years,
parental atopy, and an obstructive lung function pattern at age
9 years. By contrast, PD100 sRaw at age 9 years was not predicted
by the degree of airway hyperresponsiveness at 16 months or
5 years of age, suggesting that hyperresponsiveness increased
gradually in asthmatic infants who continued to wheeze. To
confirm that the relationships described are not dependant upon
the presence of the four children who did not respond to
methacholine, and who were assigned an arbitrary high value, we
re-analyzed data on the 79 responder children (Table 3).
Significant results were confirmed, except for the relationship
between PD100 sRaw values at 9 years of age and clinical status at
7 years (p=0.0882).
Persistent wheezing between 5 and 9 years of age was
significantly associated with the degree of airway hyperrespon-
siveness at 7 and 9 years of age, but not with airway
hyperresponsiveness at 16 months or 5 years (Table 4). Bronchial
hyperresponsiveness was predictive of altered lung function. As
early as 16 months of age, the degree of bronchial hyperrespon-
siveness correlated with higher sRaw values and lower FEV1/
FVC values at 9 years of age (Table 4). The PD100 sRaw values at
age 5 years significantly influenced sRaw values between 5 and
9 years (Figure 3). Among factors measured at 5 years, PD100
sRaw and sRaw were independently associated with higher sRaw
values at age 9 years (Table 5).
Figure 1. Clinical progression in 83 children followed from inclusion
to 9 years of age. At each evaluation, children were divided into
symptomatic (gray part of bars) and asymptomatic (black part of bars).
Each bar represents 100% of children who completed the study (n=83).
Twenty-nine percent of children were classified as symptomatic at
5 years, 7 years, and 9 years, and were classified as persistent wheezers.
Forty-six percent of children were intermittently classified as symptom-
atic (intermittent wheezers), and 25% of children were classified as
asymptomatic at all three evaluations (asymptomatic children).
doi:10.1371/journal.pone.0001180.g001
Table 2. Univariate analysis of factors potentially associated
with sRaw and FEV1/FVC values at 9 years of age.
......................................................................
SRaw (cmH20.s) FEV1/FVC (%)
VmaxFRC (Z score) at
16 months
r=20.431; p=0.0002 NS
sRaw (cmH20.s) at 5 years r=0.371; p=0.0024 r=20.352; p=0.0043
sRaw (cmH20.s) at 7 years r=0.549; p,0.0001 r=20.403; p=0.0006
Overall clinical classification
Asymptomatic (n=21) 6.161.9 86.667.5
Intermittent (n=38) 7.561.7* 86.366.2
Persistent (n=24) 7.863.3* 81.469.0*
Clinical status at 5 years
Asymptomatic (n=52) 6.861.8 86.866.4
Symptomatic (n=31) 8.063.0* 81.868.8*
Clinical status at 7 years
Asymptomatic (n=38) 6.661.8 86.167.3
Symptomatic (n=45) 7.862.7* 83.868.1
Clinical status at 9 years
Asymptomatic (n=30) 6.760.4 86.667.3
Symptomatic (n=53) 7.560.4 83.967.9
Number of severe
exacerbations between
ages 5 and 9 years
None (n=42) 6.762.0 86.366.9
One (n=20) 7.461.6 86.566.7
Two or more (n=18) 8.463.4* 79.968.8*
Parental atopy
Absence (n=42) 7.161.9 86.167.5
Presence (n=36) 7.462.9 83.368.0
Personal atopy
No positive skin tests (n=49) 7.562.3 85.167.6
$1positive skin test (n=24) 6.862.6 83.768.7
Severe exacerbations were defined by the need for oral steroids or an
emergency visit. Parental atopy was defined by the diagnosis of asthma or
allergic rhinitis in the mother or father. Linear regression was used to compare
continuous variables, and analysis of variance to compare groups. * p,0.05
when compared to reference group.
doi:10.1371/journal.pone.0001180.t002
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PLoS ONE | www.plosone.org 3 November 2007 | Issue 11 | e1180DISCUSSION
We investigated the relationship between bronchial hyperrespon-
siveness (BHR) and clinical status and lung function at 9 years of
age in children who had infantile asthma. The mid-term results of
this study, published elsewhere, showed that higher bronchial
hyperresponsiveness was associated with persistent symptoms at
5 years of age [9]. Nevertheless, BHR persisted in infants who
stopped wheezing. The present study, with a further four years of
follow-up, sheds new light on the links between BHR and the
persistence of symptoms and altered lung function in children who
had infantile asthma. The main results are that: 1) most infants
with recurrent wheezing still wheezed between 5 and 9 years of
age; 2) clinical status at 5 years of age strongly influenced lung
function at 9 years; and 3) bronchial hyperresponsiveness persisted
in nearly all the children and was linked to progressive loss of lung
function. One limitation of our study is to be unable to evaluate
potential impact of anti-asthmatic treatments, and especially
inhaled corticosteroids, on lung growth. Treatments delivered to
children were not systematically collected. Only 16% of children
received inhaled corticosteroids at 9 years of age.
Clinical outcome of children with infantile asthma
All the infants enrolled in this study had recurrent wheezing at
baseline. Four years later, at 5 years of age, only 37% continued to
wheeze, with or without periods of remission, in keeping with
epidemiological data [1,13]. However, 75% of the children were
still able to wheeze between 5 and 9 years of age, and nearly 30%
had persistent wheezing. The symptoms were usually mild, as only
one-quarter of the children experienced two or more episodes of
breathlessness requiring oral steroids or an emergency visit. Nearly
all the children who were still symptomatic at 5 years of age still
wheezed at 9 years of age. Interestingly, we also found that most
children who were in apparent remission at age 5 years had new
wheezing episodes between the ages of 5 and 9. The persistent
bronchial hyperresponsiveness that we previously observed in
these infants is likely to explain this finding. Similarly to our
findings, Morgan et al. found that around two-thirds of children
with early and persistent wheezing were still symptomatic at ages 8
and 11 years, and that most of them had infrequent wheezing [2].
However, these authors found that only 20% of children with early
and transient wheezing still wheezed at the age of 8 or 11 years
[2]. This discrepancy is probably due mainly to differences in the
study populations. All children in our study had infantile asthma,
defined by three or more wheezing episodes before 2 years of age,
whereas the infants in the Tucson study had only one or two
wheezing episodes. A higher frequency of symptoms during
infancy is a significant risk factor for the persistence of asthma at
school age [14].
Lung functional outcome in children with infantile
asthma
SRaw and FEV1/FVC values at 9 years of age were influenced by
clinical status at 5 years but not at 9 years. They were also
predicted by sRaw values at 5 and 7 years of age. SRaw values at
9 years even correlated with VmaxFRC at 16 months of age. In
particular, mean sRaw levels differed strongly between symptom-
atic and asymptomatic children at 5 years, and this difference
remained stable thereafter, independently of clinical outcome.
These results suggest that infantile asthma is a risk factor for early
loss of lung function, which is visible by 5 years of age and may be
irreversible thereafter. Our results support the findings of the
Tucson study, in which forced expiratory flows were significantly
lower among early and persistent wheezers than among late-onset
wheezers [2]. Our results are also in keeping with those of Lowe
and coworkers who showed that, by age 5 years, both transient
and persistent wheezers have reduced lung function compared
with non wheezers, and that the deficit is significantly greater in
persistent wheezers [15]. Finally, prospective studies in which
patients were followed up from school-age to adulthood showed
that the lung function phenotype was acquired early in childhood
and remained stable thereafter, regardless of the severity of asthma
symptoms [16,17]. The mechanisms that determine lower levels of
lung function are controversial. It has been proposed that
constitutional narrow airways predict subsequent wheezing illness
throughout infancy [1,18]. However, in our cohort of asthmatic
infants we have previously shown that low Vmax FRC values are
not significantly associated with transient wheezing but with
persistent wheezing by the age of 5 years [9]. The low VmaxFRC
values in our population are therefore likely to reflect disease
severity rather than constitutionally small airways, exposing to
persistence of symptoms and loss of lung function. Early airway
remodeling may also contribute to reduced airway caliber [19].
Figure 2. Mean sRaw values (6SEM) at each visit. A: Children were divided into 2 subgroups according to their clinical status at 5 years:
asymptomatic (n=52, circles and dashed line), and symptomatic (n=31, squares and solid line). B. Asymptomatic children at 5 years were divided
into 2 subgroups according to their clinical status at 9 years: asymptomatic (n=25, circles and dashed line), and symptomatic (n=27, squares and
solid line). * : significant difference when compared to the asymptomatic group (p,0.05).
doi:10.1371/journal.pone.0001180.g002
BHR and Lung Function Growth
PLoS ONE | www.plosone.org 4 November 2007 | Issue 11 | e1180Airway remodeling consists of structural changes associated with
chronic airway inflammation [20]. Its severity is indirectly
reflected by reduced expiratory flow rates and increased airway
resistance, both of which are due to reduced airway caliber.
Reduced airway caliber is also thought to play a role in persistent
airway hyperresponsiveness to methacholine [21]. Our results
support a link between increased airway resistance and higher
BHR, and also a role of bronchial hyperresponsiveness in
impaired lung function.
Relationship between bronchial
hyperresponsiveness and loss of lung function
Nearly all the children still responded to methacholine at 5 years
of age, even those who were apparently in durable remission. This
could contribute to symptom recurrence after a period of
remission, as observed in our cohort between 5 and 9 years of
age. Silent bronchial hyperresponsiveness increased the risk of
wheezing and shortness of breath during follow-up among
formerly asymptomatic patients [22–24]. Similarly, persistent
BHR was found to significantly increase the risk of symptom
relapse [17]. This underlying persistent component of BHR is
thought to relate to airway remodeling [21]. It was previously
suggested that this form of BHR detected in school children was
a strong determinant of the future pattern of growth of airway
function [20]. Our present study demonstrates that, as early as
infancy, BHR itself is predictive of impaired lung function in
children, strongly pointing to early airway remodeling in infantile
asthma. Indeed, a high level of BHR at 16 months of age
predicted reduced airway caliber at 9 years of age, as reflected by
high sRaw and low FEV1/FVC values. In a recent study, no
structural changes were observed by bronchial biopsy in wheezing
infants [25]. The younger age and heterogeneity of the infants
participating in this study may explain this apparent discrepancy.
We also found that higher BHR at 5 years of age was significantly
and independently associated with impaired growth of pulmonary
function between 5 and 9 years of age. These findings are in line
with previous reports. Indeed, FEV1 and BHR in asthmatic
children were found to be independent predictors of FEV1 in
adulthood [4]. Similarly, early airway hyperresponsiveness was
associated with a decreased baseline FEV1 by school age [7].
Recently, Illi and coworkers found that BHR at 7 years of age was
a significant predictor of baseline lung function at ages 7, 10, and
Table 3. Univariate analysis of factors associated with PD100
sRaw values at 9 years of age.
......................................................................
PD100 sRaw (log) at 9 years
All children
(n=83)
Responder
children (n=79)
VmaxFRC (Z score) at
16 months
r=0.270; p=0.0269 r=0.264; p=0.0310
sRaw (cmH20.s) at 5 years NS r=20.322; p=0.0130
sRaw (cmH20.s) at 9 years r=20.266; p=0.0203 r=20.323; p=0.0053
FEV1/FVC (%) at 9 years r=0.382; p=0.0007 r=0.375; p=0.0010
PD15 PtcO2 (log) at
16 months
NS NS
PD100 sRaw (log) at 5 years NS r=0.361; p=0.0017
PD100 sRaw (log) at 7 years r=0.429; p=0.0002 r=0.501; p,0.0001
Overall clinical classification
Asymptomatic (n=21) 2.56860.342 2.56860.342
Intermittent (n=38) 2.46960.435 2.35560.305*
Persistent (n=24) 2.24560.260* 2.24560.260*
Clinical status at 5 years
Asymptomatic (n=52) 2.53060.389 2.47660.333
Symptomatic (n=31) 2.26660.323* 2.22560.243*
Clinical status at 7 years
Asymptomatic (n=38) 2.52860.418 2.45360.344
Symptomatic (n=45) 2.34860.342* 2.32260.302
Clinical status at 9 years
Asymptomatic (n=30) 2.54060.362 2.51160.331
Symptomatic (n=53) 2.37060.390 (p,0.06) 2.30360.297*
Number of severe
exacerbations between
ages 5 and 9 years
p=0.0028 (ANOVA)
None (n=42) 2.50360.381 2.46660.333
One (n=20) 2.54060.409 2.44160.299
Two or more (n=18) 2.16360.217* 2.15460.217*
Parental atopy p=0.0293 (ANOVA)
Absence (n=42) 2.51260.381 2.47560.335
Presence (n=36) 2.32360.381* 2.29160.290*
Personal atopy
No positive skin tests
(n=49)
2.41660.385 2.38260.307
$1 positive skin test
(n=24)
2.33360.336 (NS) 2.28560.253 (NS)
Data were analyzed with all children, and after exclusion of non responders to
methacholine challenge. Severe exacerbations were defined as the need for oral
steroids or an emergency visit. Parental atopy was defined by a diagnosis of
asthma or allergic rhinitis in the mother or father. Linear regression was used to
compare continuous variables, and analysis of variance to compare groups. *
significance in post-hoc analysis.
doi:10.1371/journal.pone.0001180.t003
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Table 4. Relationship between the degree of bronchial
hyperresponsiveness at 16 months and 5, 7 and 9 years of
age, and the persistence of symptoms or lung function
impairment at 9 years of age.
......................................................................
OR (95% CI) p value
Risk=persistent wheezing between 5 and 9 years of age
PD15 PtCO2 (log) at 16 months 0.646 (0.214–1.955) NS
PD100 sRaw (log) at 5 years 0.217 (0.038–1.243) NS
PD100 sRaw (log) at 7 years 0.033 (0.004–0.262) 0.0013
PD100 sRaw (log) at 9 years 0.062 (0.008–0.487) 0.0082
Risk=sRaw$median value at age 9 years
PD15 PtCO2 (log) at 16 months 0.198 (0.074–0.531) 0.0013
PD100 sRaw (log) at 5 years 0.251 (0.070–0.897) 0.0334
PD100 sRaw (log) at 7 years 0.159 (0.040–0.626) 0.0085
PD100 sRaw (log) at 9 years 0.253 (0.071–0.903) 0.0342
Risk=FEV1/FVC,median value at age 9 years
PD15 PtCO2 (log) at 16 months 0.402 (0.165–0.983) 0.0457
PD100 sRaw (log) at 5 years 0.907 (0.275–2.991) NS
PD100 sRaw (log) at 7 years 0.132 (0.032–0.544) 0.0051
PD100 sRaw (log) at 9 years 0.027 (0.004–0.185) 0.0002
The risks were of being a persistent wheezer between 5 and 9 years of age, of
having an sRaw value at or above the median value of the study population at
9 years of age, and of having an FEV1/FVC value below the median value of the
population at 9 years of age. Median values were 7.0 cmH2O.s for sRaw and
85.5% for FEV1/FVC. Odds ratios were obtained by logistic regression.
doi:10.1371/journal.pone.0001180.t004
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PLoS ONE | www.plosone.org 5 November 2007 | Issue 11 | e118013 years, and suggested that BHR was the intermediate step in the
causal pathway linking early-life sensitization to decrements in
lung function at school age [26]. Neither parental nor personal
atopy was linked to impaired lung function in our study. Similarly,
Yang and coworkers found that pulmonary function in asthmatic
children was not influenced by atopy, the serum IgE level or the
total eosinophil count, but that it was significantly associated with
the degree of BHR [27]. This suggests that factors other than
atopy are involved in the onset of BHR in asthmatic infants.
The results of this study therefore support the hypothesis that
persistent infantile asthma is associated with an early increase in
airway responsiveness, and that this contributes to functional
pulmonary impairment.
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Regression
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sRaw (cm H20.s) 0.352 0.140 to 0.564 0.0015
PD100 sRaw (log) 21.607 22.878 to 20.336 0.0141
Clinical group 0.023 21.048 to 1.095 0.9658
Parameters obtained at 5 years of age that correlated with 9-year sRaw values
in univariate analysis were included as independent variables.
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Figure 3. SRaw measurements at ages 5, 7 and 9 years according to
the degree of bronchial hyperresponsiveness at age 5 years: children
with PD100 sRaw below (circles) and above (squares) the median
value of the population. *: p,0.008 between groups.
doi:10.1371/journal.pone.0001180.g003
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